KEY TAKEAWAYS
- The study aimed to investigate the prognostic significance of Immunoscore® in ccRCC patients.
- Researchers noticed no association between immune cell score and survival, suggesting its limited prognostic utility in ccRCC patients.
Immunoscore® is a recognized prognostic parameter reliant on the densities of lymphocyte populations within the tumor center and invasive margin. Established in colorectal cancer, a higher Immunoscore® correlates with extended survival. Emerging evidence suggests its potential prognostic utility in clear-cell renal cell carcinoma (ccRCC).
Jonne Åkerla and the team aimed to evaluate the prognostic significance of immune cell score in ccRCC.
Researchers performed an inclusive analysis encompassing all patients with ccRCC who underwent surgery between 2007 and 2020 at Central Finland Central Hospital. CD3+ and CD8+ cell densities were calculated from tissue samples to determine the immune cell score following Immunoscore® principles. Receiver-operating characteristic analysis, Kaplan-Meier survival curve, and Cox regression were employed to evaluate the association between immune cell score and survival outcomes.
About 203 patients (mean age 66.5 years) were identified, with a median follow-up time of 6.2 years. Patients were categorized into low, intermediate, and high immune cell score groups. In Cox regression analysis adjusted with age, sex, and Charlson Comorbidity Index, no significant differences in disease-specific mortality were observed among the three groups. Hazard ratios (HRs) for disease-specific mortality were 0.93 (95% confidence interval [CI] 0.48-1.79) and 1.12 (0.52-2.37) for intermediate- and high-immune cell score groups compared to the low-immune cell score group, respectively.
The study concluded no association between immune cell score and survival was observed in ccRCC. These findings suggest that immune cell score may not serve as a prognostic tool in this context.
Source: https://pubmed.ncbi.nlm.nih.gov/38578213/
Åkerla J, Helminen O, Väyrynen JP, et al. (2024). “CD3+ and CD8+ T cell-based immune cell score as a prognostic factor in clear-cell renal cell carcinoma.” Acta Oncol. 2024 Mar 28;63:105-110. doi: 10.2340/1651-226X.2024.19690. PMID: 38578213.
